Antonio Bertoletti, MD, is a leading expert in viral hepatitis, particularly the immunopathogenesis of HBV infection. Trained in Infectious Diseases at the University of Parma, he pioneered the first characterization of HBV-specific cytotoxic T cells during his time at The Scripps Research Institute. He subsequently held research and teaching positions at the University of Parma, the MRC Unit in The Gambia, and University College London before moving to Singapore, where he directed the Infection and Immunity Program at A*STAR’s Singapore Institute for Clinical Sciences and is now Professor at Duke-NUS Medical School’s Emerging Viral Disease Program. Founder of Lion TCR, a biotech company developing TCR-based immunotherapies for virus-related cancers and chronic infections, he has led first-in-human clinical trials for HBV-related hepatocellular carcinoma. He received the Singapore Translational Research Award three consecutive times (2013-2018-2024). His current work focuses on TCR-redirected T cell therapies for HBV and liver cancer, as well as immune responses in chronic HBV and COVID-19, with landmark studies published in Nature and other top journals.